Literature DB >> 33766116

CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

Sock Hoai Chan1, Jianbang Chiang1, Joanne Ngeow2,3,4.   

Abstract

Although CDKN2A is well-known as a susceptibility gene for melanoma and pancreatic cancer, germline variants have also been anecdotally associated with a broader range of neoplasms including neural system tumors, head and neck squamous cell carcinomas, breast carcinomas, as well as sarcomas. The CDKN2A gene encodes for two distinct tumor suppressor proteins, p16INK4A and p14ARF, however, the independent association of germline alterations affecting these two proteins with cancer is under-appreciated. Here, we reviewed CDKN2A germline alterations reported among individuals and families with cancer in the literature, specifically addressing the cancer phenotypes in relation to the molecular consequence on p16INK4A and p14ARF. While melanoma is observed to associate with variants affecting both p16INK4A and p14ARF transcripts, it is noted that variants affecting p14ARF are more frequently observed with a heterogenous range of cancers. Finally, we reflected on the implications of this inferred genotype-phenotype association in clinical practice and proposed that clinical management of CDKN2A germline variant carriers should involve dedicated cancer genetics services, with multidisciplinary input from various healthcare professionals.

Entities:  

Keywords:  CDKN2A; Cancer predisposition; p14ARF; p16INK4A

Year:  2021        PMID: 33766116     DOI: 10.1186/s13053-021-00178-x

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


  96 in total

1.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

2.  Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.

Authors:  Chunling Hu; Steven N Hart; Eric C Polley; Rohan Gnanaolivu; Hermela Shimelis; Kun Y Lee; Jenna Lilyquist; Jie Na; Raymond Moore; Samuel O Antwi; William R Bamlet; Kari G Chaffee; John DiCarlo; Zhong Wu; Raed Samara; Pashtoon M Kasi; Robert R McWilliams; Gloria M Petersen; Fergus J Couch
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

3.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

4.  CDKN2A germline mutations in familial pancreatic cancer.

Authors:  Detlef K Bartsch; Mercedes Sina-Frey; Sven Lang; Anja Wild; Berthold Gerdes; Peter Barth; Ralf Kress; Robert Grützmann; Mario Colombo-Benkmann; Andreas Ziegler; Stephan A Hahn; Matthias Rothmund; Harald Rieder
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

5.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

6.  Familial melanoma, pancreatic cancer and germline CDKN2A mutations.

Authors:  Alisa M Goldstein
Journal:  Hum Mutat       Date:  2004-06       Impact factor: 4.878

7.  Prospective risk of cancer in CDKN2A germline mutation carriers.

Authors:  A M Goldstein; J P Struewing; M C Fraser; M W Smith; M A Tucker
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

8.  Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred.

Authors:  A H Prowse; D C Schultz; S Guo; L Vanderveer; J Dangel; B Bove; P Cairns; M Daly; A K Godwin
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

Review 9.  Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.

Authors:  Ran Zhao; Bu Young Choi; Mee-Hyun Lee; Ann M Bode; Zigang Dong
Journal:  EBioMedicine       Date:  2016-05-03       Impact factor: 8.143

10.  Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.

Authors:  Milena Casula; Panagiotis Paliogiannis; Fabrizio Ayala; Vincenzo De Giorgi; Ignazio Stanganelli; Mario Mandalà; Maria Colombino; Antonella Manca; Maria Cristina Sini; Corrado Caracò; Paolo Antonio Ascierto; Rosanna Rita Satta; Amelia Lissia; Antonio Cossu; Giuseppe Palmieri
Journal:  BMC Cancer       Date:  2019-08-05       Impact factor: 4.430

View more
  8 in total

1.  Identification of several senescence-associated genes signature in head and neck squamous cell carcinoma.

Authors:  Jian Wang; Chong-Chang Zhou; Hong-Cun Sun; Qun Li; Jian-Dao Hu; Tao Jiang; Shao Zhou
Journal:  J Clin Lab Anal       Date:  2022-06-12       Impact factor: 3.124

2.  Study on Early Onset Melanoma and Germ-Line Mutation in CDKN2A among Patients in Imam Khomeini Hospital Complex.

Authors:  Samira Ferdosi; Mojtaba Saffari; Razieh Alishahi; Alireza Ghanadan; Reza Shirkohi
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

Review 3.  An Unanticipated Modulation of Cyclin-Dependent Kinase Inhibitors: The Role of Long Non-Coding RNAs.

Authors:  Debora Bencivenga; Emanuela Stampone; Angela Vastante; Myassar Barahmeh; Fulvio Della Ragione; Adriana Borriello
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

4.  Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer.

Authors:  Qian-Qian Wang; Yuan-Chen Zhou; Yu-Jia Zhou Ge; Geng Qin; Teng-Fei Yin; Dong-Yan Zhao; Chang Tan; Shu-Kun Yao
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

5.  CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.

Authors:  Tianyi Cheng; Yingyi Wu; Zhiyu Liu; Yi Yu; Shixue Sun; Min Guo; Baoqing Sun; Chen Huang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 6.  Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review.

Authors:  Nikola Serman; Semir Vranic; Mislav Glibo; Ljiljana Serman; Zrinka Bukvic Mokos
Journal:  Bosn J Basic Med Sci       Date:  2022-09-16       Impact factor: 3.759

Review 7.  CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.

Authors:  Mattia Garutti; Giada Targato; Silvia Buriolla; Lorenza Palmero; Alessandro Marco Minisini; Fabio Puglisi
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

8.  Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes.

Authors:  Jungyoon Choi; Guochong Jia; Wanqing Wen; Ran Tao; Jirong Long; Xiao-Ou Shu; Wei Zheng
Journal:  HGG Adv       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.